Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00026312 · OUTCOME

Event-Free Survival (EFS) of Patients From the Non-randomized Portion of the Trial

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma · Source last updated 2026-03-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Three years

What was measured

EFS for patients receiving RA + Immunotherapy following the cessation of the randomized portion of the study.

Analysis population: Eligible patients non-randomly assigned to Regimen B after halting of randomization, excluding patients with persistent disease.

Groups in this outcome

Regimen B

Non-randomly assigned to Regimen B after halting of randomization, excluding patients with persistent disease

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Regimen B1177

Reported measurements

Source class 1
Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Regimen B64.0Not reported60.267.8Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        60.2
        upper Limit
        67.8
        value
        64.0
denoms
  1. counts
    1. group Id
      OG000
      value
      1177
    units
    Participants
description
EFS for patients receiving RA + Immunotherapy following the cessation of the randomized portion of the study.
dispersion Type
95% Confidence Interval
groups
  1. description
    Non-randomly assigned to Regimen B after halting of randomization, excluding patients with persistent disease
    id
    OG000
    title
    Regimen B
param Type
NUMBER
population Description
Eligible patients non-randomly assigned to Regimen B after halting of randomization, excluding patients with persistent disease.
reporting Status
POSTED
time Frame
Three years
title
Event-Free Survival (EFS) of Patients From the Non-randomized Portion of the Trial
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice